John Henderson
Long/short equity, growth, momentum, event-driven

Accelerated Adoption Of Iridex's MicroPulse Technology Could Lead To 100% Upside

Under-followed by the Street and unknown to most investors, ophthalmology pure-play, Iridex Corp. (NASDAQ:IRIX), is both a compelling short-term and long-term investment opportunity. Buttressed by its sterling reputation as a research-oriented firm for two decades within the ophthalmic laser space, Iridex has enjoyed a quiet inflection point in recent quarters. Iridex is now a more commercially-oriented company focused on ramping up its revenues and earnings - a focus we believe will boost its shares to $20+ in the next 12-18 months.

Already profitable and generating positive cash flow, Iridex's business momentum has only just begun to turn upward. After growing its revenues 8% year-over-year in its first two quarters of the year, in the third quarter, Iridex's revenues...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details